Clinical Trials in the UK / NCT06978725
Recruiting
Phase 2/3
A Study of Brepocitinib in Adults With Cutaneous Sarcoidosis
NCT06978725 · tracked via the Priya Life Science UK tracker
Condition(s) studied
Cutaneous Sarcoidosis
Investigational drug(s) / intervention(s)
Oral Brepocitinib →Oral Placebo
Oral Brepocitinib: Oral Brepocitinib
Oral Placebo: Placebo
Study summary
This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.
Eligibility
Inclusion Criteria:
1. Adults subjects
2. Cutaneous sarcoidosis with characteristic skin biopsy histology
3. A CSAMI activity score ≥ 10
4. Weight \> 40 kg to \< 130 kg, and with a body mass index (BMI) ≤ 45 kg/m2.
Exclusion Criteria
1. History of cancer, with the exception of the following cancers with documentation of complete resection and no evidence of recurrence for ≥ 1 year: basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix.
2. High risk of thrombosis or cardiovascular disease
3. High risk of herpes zoster
4. Active or recent infection
Primary outcome measure(s)
- Part 1: Number of participants with Treatment Emergent Adverse Events and Serious Adverse Events as assessed by CTCAE v5.0 — Week 16
- Part 2: Proportion of participants achieving a reduction in Cutaneous Sarcoidosis Activity and Morphology Instrument Activity (CSAMI-A) from baseline to Week 16. — 16 Weeks
Trial sites (39)
| Facility | City | Region | Status |
|---|---|---|---|
| Clinical Trial Site | Birmingham | Alabama | Recruiting |
| Clinical Trial Site | Phoenix | Arizona | Recruiting |
| Clinical Trial Site | Tucson | Arizona | Recruiting |
| Clinical Trial Site | San Francisco | California | Recruiting |
| Clinical Trial Site | New Haven | Connecticut | Recruiting |
| Clinical Trial Site | Washington D.C. | District of Columbia | Recruiting |
| Clinical Trial Site | Atlanta | Georgia | Recruiting |
| Clinical Trial Site | Sandy Springs | Georgia | Recruiting |
| Clinical Trial Site | Chicago | Illinois | Recruiting |
| Clinical Trial Site | Chicago | Illinois | Recruiting |
| Clinical Trial Site | Kansas City | Kansas | Recruiting |
| Clinical Trial Site | Louisville | Kentucky | Recruiting |
| Clinical Trial Site | New Orleans | Louisiana | Recruiting |
| Clinical Trial Site | Baltimore | Maryland | Recruiting |
| Clinical Trial Site | Boston | Massachusetts | Recruiting |
| Clinical Trial Site | Ann Arbor | Michigan | Recruiting |
| Clinical Trial Site | Ann Arbor | Michigan | Recruiting |
| Clinical Trial Site | Troy | Michigan | Recruiting |
| Clinical Trial Site | St Louis | Missouri | Recruiting |
| Clinical Trial Site | Lebanon | New Hampshire | Recruiting |
| Clinical Trial Site | Brooklyn | New York | Recruiting |
| Clinical Trial Site | Lake Success | New York | Recruiting |
| Clinical Trial Site | New York | New York | Recruiting |
| Clinical Trial Site | New York | New York | Recruiting |
| Clinical Trial Site | Rochester | New York | Recruiting |
| Clinical Trial Site | Chapel Hill | North Carolina | Recruiting |
| Clinical Trial Site | Durham | North Carolina | Recruiting |
| Clinical Trial Site | Greenville | North Carolina | Recruiting |
| Clinical Trial Site | Cleveland | Ohio | Recruiting |
| Clinical Trial Site | Fairborn | Ohio | Recruiting |
| Clinical Trial Site | Hershey | Pennsylvania | Recruiting |
| Clinical Trial Site | Philadelphia | Pennsylvania | Recruiting |
| Clinical Trial Site | Philadelphia | Pennsylvania | Recruiting |
| Clinical Trial Site | Charleston | South Carolina | Recruiting |
| Clinical Trial Site | Houston | Texas | Recruiting |
| Clinical Trial Site | Norfolk | Virginia | Recruiting |
| Clinical Trial Site | Richmond | Virginia | Recruiting |
| Clinical Trial Site | Madison | Wisconsin | Recruiting |
| Clinical Trial Site | Milwaukee | Wisconsin | Recruiting |
More Priovant Therapeutics, Inc. trials in the UK
Official registry record
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06978725 on ClinicalTrials.gov ↗ ← All trials in the UK